Asterisk

What Asterisk does

Asterisk Lifesciences is a UK-headquartered pharmaceutical company founded in 1995, headquartered in Ilford, London, with 101-250 employees. The company operates as a pharmaceutical distributor and licensing partner, reaching 64+ regulated and emerging markets including recent expansion into African markets such as Angola and Ghana. Its core business spans in-licensing, out-licensing, and co-marketing of pharmaceutical products across multiple therapeutic areas and dosage forms.

The company does not own primary manufacturing facilities; instead, it leverages a partner manufacturing network across India, Spain, Germany, and the USA. This asset-light model allows Asterisk to focus on regulatory navigation, product licensing, and commercial distribution rather than capital-intensive production. It holds a broad set of regulatory certifications including EU GMP, US FDA, PICS, WHO, Health Canada, TGA, INVIMA, and ANVISA, supporting market access across both highly regulated and emerging jurisdictions.

The business model is B2B pharmaceutical distribution combined with licensing economics. Revenue is generated through product sales to wholesalers, hospitals, pharmacies, and government health authorities in each served market, supplemented by licensing and co-marketing arrangements. The company is privately held with no disclosed institutional investors, funding rounds, M&A activity, or AI/technology capabilities.

Name

Asterisk

Legal name

Asterisk Lifesciences Ltd

Website

https://asterisklifesciences.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

101–250 employees

Short description

Asterisk Lifesciences is a UK-based pharmaceutical distributor and licensing partner, founded in 1995, operating across 64+ markets through partner manufacturing in India, Spain, Germany, and the USA. It serves wholesalers, hospitals, and pharmacies via in-licensing, out-licensing, and co-marketing.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• Pharmaceutical products
• Generic medicines
• Drug delivery systems
• Pharmaceutical licensing
• Regulatory affairs

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from selling quality pharmaceutical products across therapy segments including Cardiology, Pain and Analgesics, Gynecology, Anti-Malarial, Cephalosporin Injectable, Oncology, Diabetology, and Vitamins-Minerals-Nutrients through affiliated manufacturing and distribution partners
2. Licensing (In-licensing and Out-licensing): Revenue through in-licensing patents and molecules, and out-licensing of products and technologies to partners in participated markets for co-development and co-marketing
3. Co-marketing Services: Partnership-based co-marketing services leveraging wide network and global expertise to build brand value for partners

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Asterisk Lifesciences is a global pharmaceutical company that develops, manufactures (via EU GMP, US FDA, PIC/S and WHO approved partner facilities), and distributes a WHO pre-qualified portfolio of generic and specialty pharmaceutical products across 64+ markets. The company offers vertically integrated end-to-end capabilities including regulatory affairs, manufacturing, supply chain management, quality assurance, sales & marketing, pharmacovigilance, and in-/out-licensing and co-marketing business development services across multiple therapeutic segments.

Product overview

Asterisk Lifesciences operates as a global pharmaceutical company with a multi-faceted portfolio of products and services. The company offers a WHO pre-qualified, EU & US FDA approved product portfolio spanning multiple therapeutic segments including Cardiology, Pain and Analgesics, Gynecology, Anti-Malarial, Cephalosporin Injectable, Oncology, Diabetology, and Vitamins-Minerals-Nutrients. Products are manufactured across various dosage forms including oral solids (tablets, hard gelatin capsules), oral liquids (sachets), injectables, topical preparations (ointments, creams), and soft gelatin capsules at certified facilities in India, Spain, Germany, and USA. Asterisk provides end-to-end capabilities including regulatory services, manufacturing, supply chain management, quality assurance, sales and marketing, and pharmacovigilance. Business development services encompass in-licensing, out-licensing, and co-marketing partnerships across 64 markets globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Medicines

Quantifiable outcome

• Timely product registration and market launch through dedicated regulatory team of 20 personnel
• +1 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• EU GMP Approved Manufacturing Facilities (India)coreOEM/ Whitelabel/ Licensing PartnerManufacturing partnerships with EU GMP approved facilities in India producing tablets, capsules, oral liquids, topicals and powders across Maharashtra, Gujarat, Karnataka and Daman locations. Facilities hold approvals from US-FDA, MHRA, ANVISA, TGA, WHO, Health Canada, FDA Ghana, NAFDAC, and EU-GMP (PIC/S).
• EU GMP Approved Manufacturing Facilities (Spain)coreOEM/ Whitelabel/ Licensing PartnerManufacturing partnership in Spain producing tablets, hard gelatin capsules, and sachets with EUGMP and TGA approvals.
• US FDA Approved Manufacturing Facilities (Germany)coreOEM/ Whitelabel/ Licensing PartnerManufacturing partnership in Germany producing semi solids, ointments, creams, and oral liquids.
• US FDA Approved Manufacturing Facilities (USA)coreOEM/ Whitelabel/ Licensing PartnerManufacturing partnership in USA producing soft gelatin capsules with USFDA approval.
• Sales & Marketing Partners (64+ Countries)coreChannel Partner/ Reseller/ DistributorQuality-assured partnerships in over 64 countries spanning Europe, Middle East, South East Asia, Latin America, and Africa. Partners include hospitals, pharmacists, and wholesalers engaged in healthcare and drug delivery.
• Europe and US Based Pharmaceutical AffiliatescoreStrategic or Co-development PartnerEurope and US based pharmaceutical affiliates equipped to adhere to EU compliance requirements and meet global pharmacovigilance standards.

Scale indicators4 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• Cipla: Major India-headquartered global generic pharmaceutical company with strong emerging-market distribution across Africa, Southeast Asia, and other developing regions. Comparable vertical integration from manufacturing through distribution and similar multi-therapy portfolio approach.
• Aspen Pharmacare: South Africa-headquartered specialty pharmaceutical company with strong distribution across African emerging markets and global pharmaceutical presence. Comparable emerging-market distribution focus and specialty pharma licensing/out-licensing activity.
• Dr. Reddy's Laboratories: India-headquartered global pharmaceutical company with integrated API-to-distribution capabilities across generics, biosimilars, and OTC. Comparable vertical integration, multi-market regulatory footprint, and emerging-markets distribution focus.
• Strides Pharma: India-based generic pharmaceutical company with global distribution and licensing across emerging markets and regulated geographies. Directly comparable global licensing/distribution business model with similar focus on difficult-to-manufacture generics.
• Aurobindo Pharma: India-based vertically integrated generic pharmaceutical manufacturer with global distribution footprint across regulated and emerging markets. Directly comparable multi-dosage form manufacturing and broad therapeutic area portfolio.

Broad incumbents

• Sun Pharmaceutical Industries: Largest specialty generic pharmaceutical company in India with global footprint spanning US, India, and emerging markets. Operates in the same multi-therapy, multi-dosage form generic pharmaceutical segment with broader scale and USFDA-approved owned manufacturing.
• Viatris: Global pharmaceutical company formed from Mylan and Upjohn, with extensive generic and specialty pharmaceutical portfolio distributed across 165+ countries. Broad incumbent in global generic pharmaceutical distribution including emerging markets.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive global distribution network across specialty and generic categories. Overlaps with Asterisk's specialty pharma distribution and difficult-to-manufacture product positioning.

Emerging players

• AdvaCare Pharma: Global pharmaceutical company focused on manufacturing and distribution of generics, specialty pharmaceuticals, and consumer health products across emerging markets. Comparable emerging-market distribution focus with portfolio breadth across multiple therapy areas.

Regional players

• STADA Arzneimittel: Germany-headquartered European-focused generic and specialty pharmaceutical company with distribution across European markets. Comparable European-headquartered specialty pharma distribution business with multi-dosage form generics portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/asterisklifesciences

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Asterisk